Renal Cell Carcinoma
Renal Cell Carcinoma
Advertisement
Zachary BessetteAdvanced Renal Cell Carcinoma | September 20, 2023
The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.
Read More
Emily MenendeznccRCC | September 14, 2023
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
Emily MenendezAdvanced Renal Cell Carcinoma | September 8, 2023
Improved PFS was associated with negative surgical margins and no 30-day surgical complications, plus pathologic downstaging.
Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
Akhil Abraham Saji, MDLocalized Prostate Cancer | September 5, 2023
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Emily MenendezLocalized Renal Cell Carcinoma | August 28, 2023
While nephrectomy is a common treatment for kidney cancer, it can result in loss of kidney function or kidney failure.
Zachary BessetteAdvanced Renal Cell Carcinoma | August 22, 2023
Belzutifan improves PFS in adult patients with advanced RCC who have progressed on previous PD-1/PD-L1 or VEGF-TKI therapies.
Emily MenendezAdvanced Renal Cell Carcinoma | August 20, 2023
As one of the most aggressive forms of kidney cancer, there is a need for new treatment strategies for RMC.
Emily MenendezLocalized Renal Cell Carcinoma | August 11, 2023
The EVEREST trial analyzed the effectiveness of everolimus in patients with RCC who have undergone full surgical resection.
Emily MenendezAdvanced Renal Cell Carcinoma | August 11, 2023
Researchers investigated the impact of duration of exposure to antiangiogenics on immunotherapy outcomes in metastatic ccRCC.
Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Brian Rini, MD, FASCOVideo Insights | August 1, 2023
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Brian Rini, MD, FASCOVideo Insights | July 31, 2023
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
Emily MenendezAdvanced Renal Cell Carcinoma | July 28, 2023
Researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy as a first-line mRCC treatment.
Jérémie Calais, MD, MScSNMMI 2023 | July 25, 2023
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Emily MenendezAdvanced Renal Cell Carcinoma | July 19, 2023
Researchers summarized the survival outcomes of patients with mRCC treated with CN after IO-based perioperative treatments.
Emily MenendezAdvanced Renal Cell Carcinoma | July 19, 2023
Research presented at KCRS23 characterized patients with an OR in the lenvatinib plus pembrolizumab arm of the CLEAR study.
Emily MenendezAdvanced Renal Cell Carcinoma | July 19, 2023
At KCRS23, researchers presented their data on the differences in clinical outcomes in patients with synchronous and metachro
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Thomas Hutson, DO, PharmD, FACPASCO 2023 | July 17, 2023
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
Advertisement
Advertisement
Advertisement